Catherine Carpentier
Overview
Explore the profile of Catherine Carpentier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Figarella-Branger D, Colin C, Mokhtari K, Uro-Coste E, Idbaih A, Appay R, et al.
Neuro Oncol
. 2024 Oct;
27(3):755-766.
PMID: 39432559
Background: In the POLA cohort, 3 pathological groups of CNS WHO grade 3 oligodendroglioma IDH-mutant and 1p/19q co-deleted have been described: group 1 (high mitotic count only), group 2 (microvascular...
2.
Kacimi S, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, et al.
J Clin Oncol
. 2024 Oct;
43(3):329-338.
PMID: 39356975
Purpose: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV)...
3.
Picca A, Touat M, Belin L, Gourmelon C, Harlay V, Cuzzubbo S, et al.
Eur J Cancer
. 2024 Mar;
202:114034.
PMID: 38537315
Background: Novel effective treatments are needed for recurrent IDH mutant high-grade gliomas (IDHm HGGs). The aim of the multicentric, single-arm, phase II REVOLUMAB trial (NCT03925246) was to assess the efficacy...
4.
Tran S, Thomas A, Aliouat I, Karachi C, Lozano F, Mokhtari K, et al.
Neuropathol Appl Neurobiol
. 2023 Jul;
49(4):e12928.
PMID: 37503540
Aims: The distinction between CNS WHO grade 2 and grade 3 is instrumental in choosing between observational follow-up and adjuvant treatment for resected astrocytomas IDH-mutant. However, the criteria of CNS...
5.
Benusiglio P, Elder F, Touat M, Perrier A, Sanson M, Colas C, et al.
JCO Precis Oncol
. 2023 Jun;
7:e2200525.
PMID: 37262394
Purpose: The Lynch syndrome (LS)-glioma association is poorly documented. As for mismatch repair deficiency (MMRd) in glioma, a hallmark of LS-associated tumors, there are only limited data available. We determined...
6.
Esparragosa Vazquez I, Ndiaye M, Di Stefano A, Younan N, Larrieu-Ciron D, Seyve A, et al.
Eur J Neurol
. 2023 May;
30(9):2879-2883.
PMID: 37204066
Background: Pseudoprogression in gliomas has been extensively described after radiotherapy with or without chemotherapy, but not after chemotherapy alone. Here we describe the occurrence of pseudoprogression in patients with anaplastic...
7.
Salam R, Saliou A, Bielle F, Bertrand M, Antoniewski C, Carpentier C, et al.
Nat Commun
. 2023 Jan;
14(1):441.
PMID: 36707509
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, yet it remains refractory to systemic therapy. Elimination of senescent cells has emerged as a promising new treatment...
8.
Seyve A, Dehais C, Chinot O, Djelad A, Cohen-Moyal E, Bronnimann C, et al.
Neuro Oncol
. 2022 Aug;
25(3):495-507.
PMID: 35953421
Background: Incidence and characteristics of pseudoprogression in isocitrate dehydrogenase-mutant high-grade gliomas (IDHmt HGG) remain to be specifically described. Methods: We analyzed pseudoprogression characteristics and explored the possibility of pseudoprogression misdiagnosis...
9.
Verreault M, Vilchis I, Rosenberg S, Lemaire N, Schmitt C, Guehennec J, et al.
Clin Transl Med
. 2022 Jul;
12(7):e939.
PMID: 35808822
Objective: New therapeutic approaches are needed to improve the prognosis of glioblastoma (GBM) patients. Methods: With the objective of identifying alternative oncogenic mechanisms to abnormally activated epidermal growth factor receptor...
10.
Garnier L, Vidal C, Chinot O, Moyal E, Djelad A, Bronnimann C, et al.
Oncologist
. 2022 May;
27(5):414-423.
PMID: 35522558
Background: Anaplastic oligodendrogliomas IDH-mutant and 1p/19q codeleted (AO) occasionally have a poor outcome. Herein we aimed at analyzing their characteristics. Methods: We retrospectively analyzed the characteristics of 44 AO patients...